Roy S. Herbst, MD, PhD
Dr. Roy S. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, Connecticut.
Dr. Herbst has led phase 1 development of several new-generation targeted agents for non–small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. Dr. Herbst was co-leader of BATTLE-1 and co-leads the BATTLE-2 clinical trial program. He served as co-leader of the Developmental Therapeutics Program for the YCC Support Grant. Herbst’s laboratory work focuses on angiogenesis and EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from preclinical to clinical settings in multiple phase 2 and 3 studies.
Dr. Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and The New England Journal of Medicine. His work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.
Dr. Herbst was a member of the National Cancer Policy Forum, for which he organized an Institutes of Medicine meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology. Dr. Herbst is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is Vice Chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and Steering Committee Chair for the Lung Master Protocol. In 2015, his team at Yale was awarded a lung cancer SPORE by the National Cancer Institute.
Dr. Herbst earned a PhD degree in molecular cell biology from The Rockefeller University, an MD degree from Cornell University Medical College, and an MS degree in clinical translational research from Harvard University. He completed an internship and residency at Harvard Medical School, along with a clinical fellowship in medicine. He also completed a medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Roy S. Herbst, MD, PhD, reported a financial interest/relationship or affiliation in the form of Scientific advisory board: Biothera; Diatech Oncology; Kolltan Pharmaceuticals, Inc; N-of-One; Consulting fee: Eli Lilly and Co; Genentech/Roche; Gilead; Merck & Co., Inc; Pfizer, Inc; Clinical trial support/grant: Genentech, Inc.
The following PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Deborah Middleton, MS; and Jocelyn Timko, BS; and Hilary Froman, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.